WCN26-7614 A RANDOMIZED PROSPECTIVE STUDY COMPARING DESIDUSTAT AND ERYTHROPOIETIN FOR THE TREATMENT OF ANEMIA IN CHRONIC KIDNEY DISEASE PATIENTS ON PERITONEAL DIALYSIS(CAPD)

Read full text Summarise with VIRAT
Authors: Indranil Ghosh, Pavitra Manu Dogra, Shreya Rathore, Ravi Prakash, S. Sreenivasa
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Anemia in Peritoneal Dialysis (PD) patients is multifactorial, driven by reduced erythropoietin synthesis, inflammation, and iron dysregulation. Conventional erythropoiesis-stimulating agents (ESAs) correct anemia but are injectable and limited by fluctuating response and inflammation-mediated resistance. Desidustat (DESI), an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI), stimulates endogenous erythropoietin while enhancing iron mobilization and reducing inflammatory blockade.

Fields of Study & Subjects

Erythropoietin and Anemia Treatment Dialysis and Renal Disease Management Iron Metabolism and Disorders

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104267–104267
Publication date
25 March 2026
Language
EN